Behdani Fatemeh, Hebrani Paria, Naseraee Afshin, Haghighi Mehri Baghban, Akhavanrezayat Amir
Associate Professor of Psychiatry, Department of Psychiatry, Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, faculty of medicine, Mashhad University Of Medical Sciences, Mashhad, Iran.
Associate Professor of Child and Adolescent Psychiatry,Department of Psychiatry, Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, faculty of medicine, Mashhad University Of Medical Sciences, Mashhad, Iran.
J Res Med Sci. 2013 Aug;18(8):653-8.
Although most of the ADHD (Attention Deficit Hyperactivity Disorder) patients respond to stimulant drugs very well, alternative drugs are required for non respondents. It has been revealed that subgroups of patients with ADHD have omega-3 fatty acid deficiency. So, the present study was planned to illustrate the effect of omega-3 supplementation, as an add-on to methylphenidate, on ADHD patients.
In this double-blind RCT, ADHD children without any co morbidity, who had been diagnosed by a child and adolescent psychiatrist in child and adolescent university clinic, participated and were randomly divided into 2 groups. The experimental group methylphenidate plus omega-3 capsule (2000mg/d), while control group took methylphenidate plus placebo. Severity of ADHD symptoms were assessed by ADHD rating scale at the baseline and after 2, 4 and 8 weeks of treatment.
69 patients (experimental = 36, control = 33) aged 7 to 15 participated. A significant reduction of both parent's and teacher's ADHD rating scale scores in both groups was observed. Bu t it couldn't show any difference between two groups. Difference score of parent's at baseline was 1.86+- (5/40), Pv 0.262, after 2 weeks -.70+- (4/30), Pv 0.668,4 weeks. 19+- (5/60), Pv 0.902 and 8 weeks. 30+- (4/42), Pv 0.845. Difference score of Teacher's at baseline was -1.56+- (3/45), Pv 0.541, after 2 weeks -.46+- (6/24), Pv 0.888, 4 weeks. 45+- (5/41), 0.868 and 8 weeks. 73+- (4/18), Pv 0.748.
Omega-3 did not enhance the therapeutic results of methylphenidate in ADHD patients.
尽管大多数注意力缺陷多动障碍（ADHD）患者对兴奋剂药物反应良好，但无反应者需要替代药物。已发现ADHD患者亚组存在ω-3脂肪酸缺乏。因此，本研究旨在阐明补充ω-3作为哌甲酯附加治疗对ADHD患者的影响。
在这项双盲随机对照试验中，在儿童和青少年大学诊所由儿童和青少年精神科医生诊断为无任何合并症的ADHD儿童参与研究，并被随机分为两组。实验组服用哌甲酯加ω-3胶囊（2000mg/天），而对照组服用哌甲酯加安慰剂。在基线以及治疗2、4和8周后，通过ADHD评定量表评估ADHD症状的严重程度。
69名年龄在7至15岁的患者（实验组 = 36名，对照组 = 33名）参与研究。两组患者的家长和教师ADHD评定量表得分均显著降低。但两组之间未显示出任何差异。家长的差异得分在基线时为1.86±（5/40），P = 0.262，2周后为 -0.70±（4/30），P = 0.668，4周后为1.9±（5/60），P = 0.902，8周后为3.0±（4/42），P = 0.845。教师的差异得分在基线时为 -1.56±（3/45），P = 0.541，2周后为 -0.46±（6/24），P = 0.888，4周后为4.5±（5/41），P = 0.868，8周后为7.3±（4/18），P = 0.748。
ω-3并未增强哌甲酯对ADHD患者的治疗效果。
